Status:
COMPLETED
Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205)
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
4-15 years
Phase:
PHASE3
Brief Summary
The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function, symptoms, and use of rescue medication in children with persistent asthma. Ciclesonide wi...
Eligibility Criteria
Inclusion
- Main
- History of persistent bronchial asthma for at least 6 months
- FEV1 50-90% of predicted
- Main
Exclusion
- Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids
- COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function
- Respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study
- History of life-threatening asthma
- Premature birth
- Current smoking
- Smoking history with either equal or more than 10 pack-years
- Pregnancy
- Intention to become pregnant during the course of the study
- Breast feeding
- Lack of safe contraception
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00163410
Start Date
April 1 2003
End Date
December 1 2004
Last Update
December 2 2016
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Altana Pharma/Nycomed
Ahmedabad, India, 380 018
2
Altana Pharma/Nycomed
Bangalore, India, 560 034
3
Altana Pharma/Nycomed
Chandigarh, India, 160 012
4
Altana Pharma/Nycomed
Coimbatore, India, 641 004